Barbara Waßmann

Goethe University Frankfurt — Germany

Medicine · Health Sciences

27h-index4.4kcitations60works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(51), Acute Lymphoblastic Leukemia research(43), Chronic Lymphocytic Leukemia Research(32), Eosinophilic Disorders and Syndromes(21), Acute Myeloid Leukemia Research(5)

Publications60 total

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia
Leukemia·2012· 228 cited
Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.
Blood·2012· 11 cited
Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Blood·2012· 4 cited
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
Leukemia·2012· 67 cited
Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Blood·2011· 10 cited
Long-Term Outcome of 335 Adult Patients Receiving Different Schedules of Imatinib and Chemotherapy as Front-Line Treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Blood·2010· 34 cited
Imatinib and Interferon-Alpha Maintenance Therapy for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).
Blood·2009
Serial Analysis of BCR-ABL Kinase Domain Mutations Prior to and During Imatinib Treatment for Newly Diagnosed and Recurrent BCR-ABL Positive Acute Lymphoblastic Leukemia.
Blood·2009
New approaches to the treatment of adult acute lymphoblastic leukaemia
memo - Magazine of European Medical Oncology·2009· 1 cited
Minimal Residual Disease and Mutational Status Prior to and after SCT for Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Blood·2008· 4 cited
Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).
Blood·2007
More Rapid Outgrowth Kinetics of BCR-ABL Mutations in Advanced Versus Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Clinical-Translational Evidence for a Contributory Role of Non-Mutational Resistance Mechanisms.
Blood·2007· 6 cited
Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL)
Cancer·2007· 237 citedOpen Access
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Blood·2007· 249 citedOpen Access
First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe Aplastic Anemia
Haematologica·2007· 32 citedOpen Access
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
Blood·2007· 168 citedOpen Access
Imatinib in Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
Drugs·2007· 1 cited
Long Term Outcome of Patients with Steroid Refractory Acute Intestinal Graft Versus Host Disease after Treatment with Pentostatin.
Blood·2006
Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).
Blood·2006· 2 cited
Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience.
Blood·2006· 2 cited
page 1 of 3Next →

Frequent Co-authors

Oliver G. Ottmann(38), Dieter Hoelzer(25), Roman Pfeifer(24), Harald Gschaidmeier(15), D. Hoelzer(14), Anja Binckebanck(12), Urban Scheuring(11), Andreas Hochhaus(10), Patrick T. Bruck(10), Hans Martin(9), Hubert Serve(7), Nicola Goekbuget(7), Aristoteles Giagounidis(6), Matthias Stelljes(6), Patrick Brueck(6), Lydia Wunderle(5), Rainer Schwerdtfeger(5), Michael Lübbert(5), Lothar Leimer(5), Hagop M. Kantarjian(4)